Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Candriam S.C.A. cut its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 45.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 547,165 shares of the company's stock after selling 451,454 shares during the period. Candriam S.C.A. owned approximately 0.64% of Syndax Pharmaceuticals worth $7,234,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. State Street Corp boosted its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after buying an additional 148,491 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Syndax Pharmaceuticals by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after buying an additional 66,459 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after buying an additional 208,043 shares during the last quarter. Finally, First Turn Management LLC boosted its holdings in Syndax Pharmaceuticals by 85.4% in the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock worth $22,853,000 after buying an additional 546,776 shares during the last quarter.

Remove Ads

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock worth $336,087 over the last ninety days. Corporate insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock traded up $0.47 during trading on Tuesday, hitting $13.00. 1,702,724 shares of the stock traded hands, compared to its average volume of 2,330,290. The firm has a market capitalization of $1.12 billion, a P/E ratio of -3.58 and a beta of 0.92. The firm's fifty day moving average price is $14.33 and its 200-day moving average price is $16.52. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.06 and a 52-week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million. As a group, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analysts Set New Price Targets

SNDX has been the topic of several research analyst reports. Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. StockNews.com lowered shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.00.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).